These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24804300)

  • 1. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy.
    An X; Wang F; Shao Q; Wang FH; Wang ZQ; Wang ZQ; Chen C; Li C; Luo HY; Zhang DS; Xu RH; Li YH
    Cancer; 2014 Mar; 120(5):675-82. PubMed ID: 24804300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
    Kim WY; Shim SH; Jung HY; Dong M; Kim SN; Lee SJ
    Hum Pathol; 2017 Jun; 64():98-105. PubMed ID: 28428108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome.
    Lee HE; Kim MA; Lee HS; Jung EJ; Yang HK; Lee BL; Bang YJ; Kim WH
    Br J Cancer; 2012 Jul; 107(2):325-33. PubMed ID: 22644302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
    Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
    Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
    Seo S; Park SJ; Ryu MH; Park SR; Ryoo BY; Park YS; Na YS; Lee CW; Lee JK; Kang YK
    Oncotarget; 2017 May; 8(20):33844-33854. PubMed ID: 27802183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma.
    Zhang J; Guo L; Liu X; Li W; Ying J
    Oncotarget; 2017 Feb; 8(6):10264-10273. PubMed ID: 28052014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MET in gastric cancer--discarding a 10% cutoff rule.
    Metzger ML; Behrens HM; Böger C; Haag J; Krüger S; Röcken C
    Histopathology; 2016 Jan; 68(2):241-53. PubMed ID: 26033401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
    Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.
    Catenacci DV; Ang A; Liao WL; Shen J; O'Day E; Loberg RD; Cecchi F; Hembrough T; Ruzzo A; Graziano F
    Cancer; 2017 May; 123(6):1061-1070. PubMed ID: 27926778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer.
    Peng Z; Li Z; Gao J; Lu M; Gong J; Tang ET; Oliner KS; Hei YJ; Zhou H; Shen L
    Mol Cancer Ther; 2015 Nov; 14(11):2634-41. PubMed ID: 26330547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.
    Kim HS; Chon HJ; Kim H; Shin SJ; Wacheck V; Gruver AM; Kim JS; Rha SY; Chung HC
    J Surg Oncol; 2018 Jun; 117(8):1679-1686. PubMed ID: 29790169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MET expression and amplification in patients with localized gastric cancer.
    Janjigian YY; Tang LH; Coit DG; Kelsen DP; Francone TD; Weiser MR; Jhanwar SC; Shah MA
    Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):1021-7. PubMed ID: 21393565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.
    Lee J; Seo JW; Jun HJ; Ki CS; Park SH; Park YS; Lim HY; Choi MG; Bae JM; Sohn TS; Noh JH; Kim S; Jang HL; Kim JY; Kim KM; Kang WK; Park JO
    Oncol Rep; 2011 Jun; 25(6):1517-24. PubMed ID: 21424128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
    Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
    J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas.
    Nakajima M; Sawada H; Yamada Y; Watanabe A; Tatsumi M; Yamashita J; Matsuda M; Sakaguchi T; Hirao T; Nakano H
    Cancer; 1999 May; 85(9):1894-902. PubMed ID: 10223227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.
    Wang M; Liang L; Lei X; Multani A; Meric-Bernstam F; Tripathy D; Wu Y; Chen H; Zhang H
    Ann Diagn Pathol; 2018 Aug; 35():69-76. PubMed ID: 29843069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
    Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: its clinical implication and comparison with immunohistochemistry and silver in situ hybridization.
    Choi J; Lee HE; Kim MA; Jang BG; Lee HS; Kim WH
    PLoS One; 2014; 9(11):e111658. PubMed ID: 25364819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
    Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.